ClinicalTrials.gg
CompletedNCT00855933Updated Feb 8, 2013Results posted

A Controlled Clinical Study to Determine the Gingivitis Benefit of Flossing

A Phase 4 interventional study of Experimental Floss in Gingivitis, sponsored by Procter and Gamble. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-02-08.

Sponsored by Procter and Gamble · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a randomized, controlled, examiner-blind, parallel group, four week clinical study comparing brushing plus flossing to brushing alone in healthy adults with mild-to-moderate gingivitis.

02

Conditions studied

  • Gingivitis

Browse trials for

03

In context

Gingivitis

609 studies on the registry are indexed under Gingivitis; 107 are open to participants now.

This study's enrollment of 60 is close to the median of 63 across 494 interventional studies indexed under Gingivitis.

Browse Gingivitis studies →

Lead sponsor

Procter and Gamble is the lead sponsor of 83 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at least 18 years of age;
  • physically able to floss his/her teeth;
  • refrained from performing oral hygiene the morning of the Baseline visit;
  • have measurable gingivitis on at least 5 test sites;
  • in good general health.

Exclusion criteria

Exclusion Criteria:

  • severe periodontal disease
  • atypical discoloration or pigmentation in the gingival tissue;
  • meaningful malocclusion of the anterior teeth;
  • fixed facial orthodontic appliances;
  • use of antibiotics within two weeks of the baseline visit and at any time during the study;
  • any diseases or conditions that could be expected to interfere with the subject safely completing the study.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • No intervention
    Control - no flossing

    Subjects brushed thoroughly for one minute with Crest® Cavity Protection toothpaste and an Oral-B® Indicator soft, manual toothbrush once daily.

  • Experimental
    Experimental Floss

    Subjects brushed thoroughly for one minute with Crest® Cavity Protection toothpaste and an Oral-B® Indicator soft, manual toothbrush once daily. Subjects flossed once daily with the experimental floss.

    Device: Experimental Floss

Interventions

  • DeviceExperimental Floss

    Experimental Glide® floss with cetylpyridinium chloride (\~13% dry weight CPC)

    Also known as: Glide®, floss, cetylpyridinium chloride, CPC

06

What researchers measure

Primary outcomes

  1. Whole Mouth Lobene Modified Gingival Index Between the Brushing Only Group and the Brushing + Flossing Group [30 Days] Units on the MGI Scale

    A whole-mouth average Lobene Modified Gingival Index was calculated by summing the scores and dividing by the number of sites graded (excludes missing teeth \& sites not graded). Whole mouth average can range from 0 (normal) to 4 (severe inflammation). For each tooth, six gingival areas (distobuccal, buccal, mesiobuccal, mesiolingual, lingual, and distolingual) were scored using the following scale: 0=Normal (Absence of inflammation, 1=Mild inflammation (slight change in color, little change in texture) of any portion of but not the entire marginal or papillary gingival unit, 2=Mild inflammation criteria as above but involving the entire marginal or papillary gingival unit, 3=Moderate inflammation (moderate glazing, redness, edema, and/or hypertrophy) of the marginal or papillary gingival unit, 4=Severe inflammation (marked redness, edema and/or hypertrophy, spontaneous bleeding or ulceration) of the marginal or papillary gingival unit.

    Time frame: 4 weeks

07

Results

Posted Feb 8, 2013

Participant flow

Participant flow — Overall Study
MilestoneBrushing OnlyBrushing + Flossing
Started3030
Completed3029
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryWhole Mouth Lobene Modified Gingival Index Between the Brushing Only Group and the Brushing + Flossing Group [30 Days] Units on the MGI Scale

A whole-mouth average Lobene Modified Gingival Index was calculated by summing the scores and dividing by the number of sites graded (excludes missing teeth \& sites not graded). Whole mouth average can range from 0 (normal) to 4 (severe inflammation). For each tooth, six gingival areas (distobuccal, buccal, mesiobuccal, mesiolingual, lingual, and distolingual) were scored using the following scale: 0=Normal (Absence of inflammation, 1=Mild inflammation (slight change in color, little change in texture) of any portion of but not the entire marginal or papillary gingival unit, 2=Mild inflammation criteria as above but involving the entire marginal or papillary gingival unit, 3=Moderate inflammation (moderate glazing, redness, edema, and/or hypertrophy) of the marginal or papillary gingival unit, 4=Severe inflammation (marked redness, edema and/or hypertrophy, spontaneous bleeding or ulceration) of the marginal or papillary gingival unit.

Time frame:
4 weeks
Reported as:
Mean · units on a scale
Whole Mouth Lobene Modified Gingival Index Between the Brushing Only Group and the Brushing + Flossing Group [30 Days] Units on the MGI Scale
units on a scaleBrushing OnlyBrushing + Flossing
Whole Mouth Lobene Modified Gingival Index Between the Brushing Only Group and the Brushing + Flossing Group [30 Days] Units on the MGI Scale1.84 ± 0.0471.73 ± 0.047
Statistical analysis
  • Brushing Only vs Brushing + Flossing · ANCOVA · p = 0.126 (a priori threshold for statistical significance = 0.05) · Mean difference (final values): 0.10 · 95% CI -0.03 to 0.242-sided with the significance level set at 5%

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brushing Only—0/30 (0%)0/30 (0%)
Brushing + Flossing—0/30 (0%)0/30 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Brushing OnlyBrushing + FlossingTotal
<=18 years000
Between 18 and 65 years303060
>=65 years000
Age Continuous
Age Continuous(years)Brushing OnlyBrushing + FlossingTotal
Mean29.5 ± 10.0827.8 ± 9.4128.7 ± 9.71
Sex: Female, Male
Sex: Female, Male(Participants)Brushing OnlyBrushing + FlossingTotal
Female262753
Male437
Region of Enrollment
Region of Enrollment(participants)Brushing OnlyBrushing + FlossingTotal
Guatemala303060
Whole Mouth Average Lobene Modified Gingival Index
Whole Mouth Average Lobene Modified Gingival Index(Units on a scale)Brushing OnlyBrushing + FlossingTotal
Mean2.41 ± 0.282.38 ± 0.272.40 ± 0.27
08

Study locations

2 sites
  • Dr. Geza Terézhalmy, DDS , MA
    San Antonio, Texas 78229, United States
  • Luis R. Archila, DDS
    Guatemala City, Guatemala
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 8, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00855933
Lead sponsor
Procter and Gamble
Responsible party
Sponsor
First posted
Mar 5, 2009
Start date
Jan 2009
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Feb 8, 2013
Last update
Feb 8, 2013

Study contacts

Aaron Biesbrock, DMD, PhD
study director · Procter and Gamble

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion